Publications by authors named "W A Were"
Article Synopsis
- - Children and neonates are particularly vulnerable to antimicrobial resistance, making the development of suitable antibacterial agents for their use critical due to the existing barriers in research and development.
- - In late 2022, WHO launched the first Paediatric Drug Optimisation (PADO) exercise focused on antibiotics, which aimed to identify and prioritize antibiotics for research and development that can address serious bacterial infections in children, especially in high-burden regions.
- - The Review discusses the processes and outcomes of the PADO exercise, outlines follow-up actions for implementation, and emphasizes the importance of collaboration in improving access to essential medicines for children globally.
Core outcome measurement set for research and clinical practice in post-COVID-19 condition (long COVID) in children and young people: an international Delphi consensus study "PC-COS Children".
Eur Respir J
March 2024
The coronavirus disease 2019 (COVID-19) pandemic substantially impacted different age groups, with children and young people not exempted. Many have experienced enduring health consequences. Presently, there is no consensus on the health outcomes to assess in children and young people with post-COVID-19 condition.
View Article and Find Full Text PDFArticle Synopsis
- The WHO Model List of Essential Medicines (EML) focuses on prioritizing medicines that are crucial for global public health, particularly in the context of antibiotic use and resistance.
- In response to the rise of antimicrobial resistance, the EML introduced a new classification system called AWaRe, which categorizes antibiotics into Access, Watch, and Reserve groups to guide appropriate usage.
- The 2023 AWaRe classification includes 41 essential antibiotics and aims to enhance global antibiotic prescribing practices, promoting the use of Access antibiotics to optimize treatment and reduce misuse to prolong the effectiveness of these medications.
Background: Single low-dose primaquine (SLDPQ) effectively blocks the transmission of Plasmodium falciparum malaria, but anxiety remains regarding its haemolytic potential in patients with glucose-6-phopshate dehydrogenase (G6PD) deficiency. We, therefore, examined the independent effects of several factors on haemoglobin (Hb) dynamics in falciparum-infected children with a particular interest in SLDPQ and G6PD status.
Methods: This randomised, double-blind, placebo-controlled, safety trial was conducted in Congolese and Ugandan children aged 6 months-11 years with acute uncomplicated P.
Background: There are no pharmacokinetic data of single low dose primaquine (SLDPQ) as transmission blocking in African children with acute Plasmodium falciparum and glucose-6-phosphate dehydrogenase deficiency (G6PDd).
Methods: Primaquine pharmacokinetics of age-dosed SLDPQ (shown previously to be gametocytocidal with similar tolerability as placebo) were characterised in falciparum-infected Ugandan and Congolese children aged 6 months to 11 years, treated on admission with standard 3-day dihydroartemisinin-piperaquine or artemether-lumefantrine plus SLDPQ: 6 m-<1 y: 1.25 mg, 1-5 y: 2.